18–19 November
from 10am–12pm ET each day

Future
Regulatory
Summit2026

The two-day free virtual summit for regulatory leaders

We can’t wait either

Enter your email to register to the event
00
:
00
:
00
:
00
Collaborative Review
ICH M11
eCTD 4.0
AI in RegOps
RIM Modernization
HL7 FHIR & Global Standards
DATA-NATIVE SUBMISSIONS
GOVERNANCE
DATA QUALITY
Collaborative Review
ICH M11
eCTD 4.0
AI in RegOps
RIM Modernization
HL7 FHIR & Global Standards
DATA-NATIVE SUBMISSIONS
GOVERNANCE
DATA QUALITY
Why attend

The submission playbook is being rewritten.

Regulatory submissions are entering their biggest shift in a generation. In two focused days, we'll cut through the noise on the questions leaders are actually facing — whether your data is an asset or a liability, if your RIM can keep pace with your ambitions, what reliance really means in the cloud era, and where AI genuinely earns its place in RegOps.

Agenda

Day 1: Five sessions. Zero filler.

10AM
18/11

Embracing a New Era: First Look at the Fall 2026 RIM Benchmark — Opening Keynote

A convergence of change has ushered in a new era for life sciences, with significant impact and opportunity for regulatory professionals. The harder question is what it actually takes to benefit from it.

Steve Gens opens the summit with the first public look at the October 2026 Regulatory Intelligence and Organizational Implications of AI survey couple with the recent Operational Excellence and World Class RIM benchmark. Drawing on more than a decade of tracking the same measures across the industry, he will set out what has changed, what has not, and what this year's data suggests about where regulatory organisations are heading.

Read more

The session covers fourth-generation information architecture and what it means in practice, the new ways of working and cross-functional structures the transition demands, and the latest evidence on the organisational impact of AI. Running underneath is a consistent finding from the benchmark: technology alone does not separate the organisations that perform from those that do not.

Steve Gens
Managing Partner, Gens & Associates

A convergence of change has ushered in a new era for life sciences, with significant impact and opportunity for regulatory professionals. The harder question is what it actually takes to benefit from it.

Steve Gens opens the summit with the first public look at the October 2026 Regulatory Intelligence and Organizational Implications of AI survey couple with the recent Operational Excellence and World Class RIM benchmark. Drawing on more than a decade of tracking the same measures across the industry, he will set out what has changed, what has not, and what this year's data suggests about where regulatory organisations are heading.

Read more

The session covers fourth-generation information architecture and what it means in practice, the new ways of working and cross-functional structures the transition demands, and the latest evidence on the organisational impact of AI. Running underneath is a consistent finding from the benchmark: technology alone does not separate the organisations that perform from those that do not.

10:15AM
18/11

RIM in the New Era: Are Your Systems Keeping Up With Your Ambitions?

Most organizations have a RIM system. Far fewer have a RIM capability. The platform goes live, the program team disbands, and eighteen months later the spreadsheets are quietly back in circulation while the roadmap that justified the investment is still sitting on slide 14. Meanwhile, eCTD 4.0 moves from pilot to reality.

Read more

This panel is about the distance between technical go-live and business go-live, with RIM system owners and 4.0 practitioners who have run modernization programs end to end, including the parts that didn't go to plan.

Matt Neal
Executive Director, Global Regulatory Operations Strategy & Innovation, BeOne Medicines
Brooke Casselberry
VP, Advisory & Delivery, Epista Life Science
Katherine Novak
Director, Advisory & Delivery, Epista Life Science
Kevin Tompkins
Executive Director, Head of Regulatory Information and Submission Management, Bristol Myers Squibb
Christine Glenn
Head, Global Submissions Management, Sanofi

Most organizations have a RIM system. Far fewer have a RIM capability. The platform goes live, the program team disbands, and eighteen months later the spreadsheets are quietly back in circulation while the roadmap that justified the investment is still sitting on slide 14. Meanwhile, eCTD 4.0 moves from pilot to reality.

Read more

This panel is about the distance between technical go-live and business go-live, with RIM system owners and 4.0 practitioners who have run modernization programs end to end, including the parts that didn't go to plan.

11AM
18/11

Tech Spotlight: Kivo.io

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Read more

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur

Kevin Tate
CRO, Kivo.io
Tobin Zolman
CEO, Kivo.io

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Read more

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur

11:15AM
18/11

From Data Chaos to Data Capital: Why Regulatory Data Quality Is Now a Strategic Issue

Regulatory data has been treated as a byproduct of submissions for decades: created to fill a field, satisfy a requirement, and get a dossier out the door. PQ-CMC, ePI and AI all now ask the same question of it – is this structured, governed and trusted enough to reuse? And for most organizations the honest answer is still no.

Read more

This opening panel looks at what changes when data quality stops being a cleanup exercise and starts being treated as capital, with named owners, agreed standards and a measurable return.

Mike Abernathy
AVP, Global Regulatory Affairs, Amgen
Joan Cheung
Principal Consultant, Epista Life Science
Brooke Casselberry
VP, Advisory & Delivery, Epista Life Science
Ashley Burt
Head of Global Regulatory, Quality & Safety (RQS) Operations, Merck Healthcare
Vanni Carapetian
Executive Director, Strategy & Operations, CMC Regulatory Affairs, Gilead

Regulatory data has been treated as a byproduct of submissions for decades: created to fill a field, satisfy a requirement, and get a dossier out the door. PQ-CMC, ePI and AI all now ask the same question of it – is this structured, governed and trusted enough to reuse? And for most organizations the honest answer is still no.

Read more

This opening panel looks at what changes when data quality stops being a cleanup exercise and starts being treated as capital, with named owners, agreed standards and a measurable return.

12PM
18/11

Tech Spotlight: DAQUMA

Life sciences has spent years waiting for perfect data before starting with AI. But AI doesn't have to wait for the foundation. Used well, it can help build it. Building on the discussion of regulatory data quality, this session shows how leading organizations are using AI to expose, remediate and govern data quality rather than waiting for it to be fixed. Through real-world GxP examples, DAQUMA will explore why trust, auditability and human accountability make this work, and whether your organization is ready to trust AI to help get there.

Read more

DAQUMA connects Clinical, Quality, Regulatory, and Safety systems, putting AI agents to work, analyzing data, assisting your teams, and delivering actionable insight in seconds. From document intake to review and quality checks, it turns manual processes into fast, compliant workflows, built on a governed platform with compliance at its core.

Sille Lie Barrett
Founding Partner & Head of Services, DAQUMA
Peter Smedegaard Andersen
Founding Partner & CEO, DAQUMA

Life sciences has spent years waiting for perfect data before starting with AI. But AI doesn't have to wait for the foundation. Used well, it can help build it. Building on the discussion of regulatory data quality, this session shows how leading organizations are using AI to expose, remediate and govern data quality rather than waiting for it to be fixed. Through real-world GxP examples, DAQUMA will explore why trust, auditability and human accountability make this work, and whether your organization is ready to trust AI to help get there.

Read more

DAQUMA connects Clinical, Quality, Regulatory, and Safety systems, putting AI agents to work, analyzing data, assisting your teams, and delivering actionable insight in seconds. From document intake to review and quality checks, it turns manual processes into fast, compliant workflows, built on a governed platform with compliance at its core.

Day 2: Five sessions. Zero filler.

10AM
19/11

Day 1 Recap

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Read more

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur

Brooke Casselberry
VP, Advisory & Delivery, Epista Life Science
Oliver Pearce
VP, Global Marketing, Epista Life Science

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Read more

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur

10:15AM
19/11

AI in RegOps: Separating Signal from Noise

There's no shortage of AI claims aimed at regulatory teams, and very little agreement on which survive contact with a regulated process. Teams are being asked to evaluate tools faster than they can build the validation, governance and data foundations those tools depend on, and the gap between what gets demonstrated and what gets deployed keeps widening.

Read more

This closing panel is deliberately skeptical: practitioners running live AI and automation work on where it's genuinely adding value today, what had to be true before it worked, and how they validate and govern GenAI for regulatory use.

James O'Keefe
Executive Director, Head of Global Regulatory Information, Data & Systems, Takeda
Neel Patel
Director of Technology, Epista Life Science
Oliver Pearce
VP, Global Marketing, Epista Life Science
Brandon Rice
CEO & Co-founder, Weave Bio
Rita Algorri
Associate Director, Global Regulatory Affairs (CMC), Amgen

There's no shortage of AI claims aimed at regulatory teams, and very little agreement on which survive contact with a regulated process. Teams are being asked to evaluate tools faster than they can build the validation, governance and data foundations those tools depend on, and the gap between what gets demonstrated and what gets deployed keeps widening.

Read more

This closing panel is deliberately skeptical: practitioners running live AI and automation work on where it's genuinely adding value today, what had to be true before it worked, and how they validate and govern GenAI for regulatory use.

11AM
19/11

Tech Spotlight: Weave.bio

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Read more

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur

Brandon Rice
CEO & Co-founder, Weave Bio

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Read more

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur

11:15AM
19/11

The Collaboration Imperative: Reliance, Cloud, and the End of the One-Way Submission

Reliance pathways, Project Orbis, ACCESS and cloud-based regulatory spaces all point the same way: submission as a shared, structured exchange rather than a package thrown over a wall. The models exist and the pilots have run. What hasn't caught up is the operating reality inside most sponsors, where data, systems and internal governance were all built for one-way handoff.

Read more

This panel gets past the conference-slide version into what actually changes for a sponsor, what the sequencing looks like, and where the honest limits sit today.

Vada Perkins
VP,  Global Head of Regulatory Intelligence & Policy, Boehringer Ingelheim
Dominique Lagrave
Former Chief Regulatory Innovation Officer, Accumulus Technologies
Nick Rattenni
Principal Consultant, Epista Life Science
Mark Hefner
Director, Regulatory Information Management & Technology, BioMarin Pharmaceutical
Brooke Casselberry
VP, Advisory & Delivery, Epista Life Science

Reliance pathways, Project Orbis, ACCESS and cloud-based regulatory spaces all point the same way: submission as a shared, structured exchange rather than a package thrown over a wall. The models exist and the pilots have run. What hasn't caught up is the operating reality inside most sponsors, where data, systems and internal governance were all built for one-way handoff.

Read more

This panel gets past the conference-slide version into what actually changes for a sponsor, what the sequencing looks like, and where the honest limits sit today.

12PM
19/11

Tech Spotlight: cormeo

In this spotlight, we will talk about "The Future of Regulatory Collaboration", including Cloud-Based Regulatory Spaces (CBRS) which are emerging as a critical component of modern regulatory ecosystems. Regulatory authorities and Marketing Authorization Holders (MAHs) face unprecedented challenges in managing the complexity and volume of regulatory data. Traditional systems, often document-centric and siloed, struggle to accommodate the requirements of modern pharmaceutical regulations especially related to collaboration. cormeo has supported the transformation of these processes for decades, providing technology solutions for both industry and authorities, that streamline regulatory operations while ensuring compliance and data integrity.

Read more

cormeo is one of the leading provider in the fields of Smart Information Lifecycles building the trusted bridge between industry, authorities, healthcare professionals, and patients.

Christian Mehrmann
Director, Solution Portfolio, cormeo
Schei Dattner
CTO & CSO, cormeo

In this spotlight, we will talk about "The Future of Regulatory Collaboration", including Cloud-Based Regulatory Spaces (CBRS) which are emerging as a critical component of modern regulatory ecosystems. Regulatory authorities and Marketing Authorization Holders (MAHs) face unprecedented challenges in managing the complexity and volume of regulatory data. Traditional systems, often document-centric and siloed, struggle to accommodate the requirements of modern pharmaceutical regulations especially related to collaboration. cormeo has supported the transformation of these processes for decades, providing technology solutions for both industry and authorities, that streamline regulatory operations while ensuring compliance and data integrity.

Read more

cormeo is one of the leading provider in the fields of Smart Information Lifecycles building the trusted bridge between industry, authorities, healthcare professionals, and patients.

A lineup you won't find anywhere else

Future Regulatory Summit is gathering the industry's leading regulatory experts from across the globe around one virtual table. Our lineup is a "who's who" of the people shaping the future of regulatory submissions at some of the world's biggest and most innovative life science companies. You won't find this anywhere else.

Register for free
featured speakers

The people shaping what's next

Steve Gens

Managing Partner
Gens & Associates

Brooke Casselberry

VP, Advisory & Delivery
Epista

Matt Neal

Executive Director, Global Regulatory Operations Strategy & Innovation
BeOne Medicines

Vada Perkins

VP, Global Head of Regulatory Intelligence & Policy
Boehringer Ingelheim

Kevin Tompkins

Executive Director, Head of Regulatory Information and Submission Management
Bristol Myers Squibb

Vanni Carapetian

Executive Director, Strategy & Operations, CMC Regulatory Affairs
Gilead

Marc Hefner

Director, Director, Regulatory Information Management and Technology
BioMarin Pharmaceutical

Mike Abernathy

AVP, Global Regulatory Affairs
Amgen

Why we're hosting this event

Putting on an event of this scale is no small feat, but we believe it's a necessary one. Right now, regulatory submissions are at the precipice of a new era—AI, CBRS, eCTD 4.0, IDMP, and many other forces are converging to form an entirely new landscape. All of these topics are being discussed, but rarely in the same room, and almost never with the goal of understanding how they will come together holistically to reshape the future. We wanted to give the community a space to come together, to learn, to ask questions, and to prepare for what's to come.

supported by
Two professionals sitting on a green couch, smiling and engaged in conversation against a backdrop of beige curtains.
tagline

Who you'll see at Future Regulatory Summit

A group of four young professionals having a conversation while seated in a modern office lounge with plants in the background.
Future REGULATORY SUMMIT

Don't miss this one

If there's one regulatory event you attend before the end of the year, it should be this one. Leading industry experts, talking about the subjects that truly matter, with an audience of your peers. Save your spot today.